Wyeth bapineuzumab data
Executive Summary
Wyeth will announce the second installment of Phase II bapineuzumab data in patients with mild to moderate Alzheimer's disease at the International Conference on Alzheimer's Disease on July 29, the firm announces in its July 23 second quarter earnings call. At the initial release of bapineuzumab results, Wyeth and development partner Elan hailed strong efficacy and acceptable safety in Alzheimer's patients who do not carry the Apolipoprotein E4 gene, though the monoclonal antibody failed to demonstrate statistical significance on the primary efficacy endpoints (1"The Pink Sheet" DAILY, June 17, 2008)